Litcius/Paper detail

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul Shaughnessy, Armin Ghobadi, Michael Bishop, Ana Alfonso Piérola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William B. Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant-Cohen, Richard T. Maziarz, Carlos Bachier

2022Blood53 citationsDOI

Topics & Concepts

CRISPRLymphomaRefractory (planetary science)MedicineB-cell lymphomaSalvage therapyOncologyInternal medicineChemotherapyBiologyGeneBiochemistryAstrobiologyCAR-T cell therapy research